Remicade (infliximab) denied as duplicate or overlapping therapy by UnitedHealthcare?

This UnitedHealthcare commercial policy (effective 02.01.2026) addresses the use of infliximab products including Avsola, Inflectra, Remicade, and Renflexis , and applies to billing codes J1745, Q5103, Q5104, and Q5121 . UHC designates Avsola and Inflectra as the preferred infliximab products for UHC commercial plans , and members already on Remicade, Renflexis, or other non-preferred infliximab product will be required to change therapy to Inflectra or Avsola unless they meet the exception criteria . To obtain Remicade specifically, the policy requires documentation of a trial of at least 14 weeks of Inflectra or Avsola resulting in minimal clinical response, OR a physician attestation that in their clinical opinion the clinical response would be expected to be superior with Remicade than with Inflectra and Avsola , or alternatively documentation of intolerance, contraindication, or adverse event to the preferred biosimilars with a physician attestation that the same event would not be expected to occur with Remicade . Indication-specific criteria require disease-appropriate step therapy — for example, ankylosing spondylitis requires history of failure to two NSAIDs at maximally indicated doses, each used for at least 4 weeks, unless contraindicated, or prior treatment with a systemic targeted immunomodulator FDA-approved for ankylosing spondylitis ; plaque psoriasis requires greater than or equal to 3% body surface area involvement, or palmoplantar, facial, or genital involvement plus failure of a topical therapy. Patients must not be receiving infliximab in combination with another systemic targeted immunomodulator (e.g., adalimumab, Cimzia, Enbrel, Orencia, Simponi, Rinvoq, Xeljanz) for treatment of the same indication , and dosing must be according to FDA-labeled dosing for the indication . Prior authorization is required, and the policy notes the patient must not have FDA-labeled contraindications and must be tested for latent TB per prescribing information, with treatment begun if positive .

- For forced biosimilar switching: cite the ACR position that coverage for non-preferred products should consider patient-specific exception criteria, and ACR has urged UHC to allow existing patients to continue on their current medication and proposed additional exception criteria for patient protection ; also reference AGA's negotiated exceptions that adult patients currently on induction of Remicade for less than 18 months will not be required to switch, and adult patients having a flare of active disease, and hence are not stable, will not be required to switch - For pediatric IBD denials of Remicade continuation: cite United's agreement to modify its coverage policy to allow pediatric patients 16 years of age and younger currently on Remicade to remain on Remicade if that is the recommendation of the treating physician , supported by NASPGHAN/AGA/ACG/ASGE consensus - For step therapy in Crohn's disease: cite the ACG Clinical Guideline for Crohn's Disease in Adults and AGA Care Pathway recommending early anti-TNF therapy for moderate-to-severe disease and high-risk features (fistulizing, stricturing, perianal, young age at diagnosis) — aligns with UHC's own high-risk criteria language - For step therapy in rheumatoid arthritis: cite the 2021 ACR Guideline for RA Treatment supporting biologic DMARDs (including TNFi) after inadequate response to methotrexate; for ankylosing spondylitis cite the 2019 ACR/SAA/SPARTAN AS Guideline strongly recommending TNFi after NSAID failure - For plaque psoriasis criteria: cite the AAD-NPF 2019 Guidelines of Care for the Management of Psoriasis with Biologics supporting infliximab for moderate-to-severe disease and special-site involvement (palmoplantar, facial, genital), matching UHC's BSA/special-site criteria - For non-medical switching/efficacy concerns: cite the NOR-SWITCH randomized controlled trial (Jørgensen et al., Lancet 2017) demonstrating non-inferiority of CT-P13 biosimilar to originator infliximab — but conversely, a documented loss of response or infusion reaction on a biosimilar meets UHC's own exception pathway for Remicade - For concomitant biologic denial: clarify in the appeal that the patient is transitioning therapies (not on simultaneous biologics) with appropriate washout, addressing UHC's combination-therapy exclusion language

## Why UnitedHealthcare Flags Remicade as Duplicate Therapy

A "duplicate therapy" denial on Remicade (infliximab, J1745) under UnitedHealthcare's commercial Medical Benefit Drug Policy is a concurrent-use NQTL — it fires when UHC's claims engine detects an open authorization or paid claim for another systemic targeted immunomodulator (adalimumab, Cimzia, Enbrel, Orencia, Simponi, Rinvoq, or Xeljanz) under the same ICD-10 indication as the infliximab request. The policy language — "must not be receiving infliximab in combination with another systemic targeted immunomodulator for treatment of the same indication" — is enforced by Optum's prior-authorization platform, not the medical director. Most of these denials are pattern-match errors: a residual adalimumab claim from a washout period, a JAK inhibitor billed for a different indication (e.g., Rinvoq for atopic dermatitis while infliximab treats Crohn's), or a sequential-switch scenario the system reads as overlap.

## The Right Channel and the Right Record

Because infliximab is medical-benefit (HCPCS J1745 / Q5103 / Q5104 / Q5121), the appeal routes through the UHC Provider Portal medical PA team — not OptumRx pharmacy appeals. Filing through OptumRx will get a "wrong benefit" rejection that wastes your 180-day ERISA clock. Pull the UHC Commercial Medical Benefit Drug Policy for Infliximab (effective 02.01.2026) and quote it back: the contraindication is concurrent use for the same indication. If the overlapping agent treats a comorbidity (psoriatic arthritis + ulcerative colitis is the classic split), submit dual ICD-10s with progress notes anchoring each biologic to its target disease, plus the prescriber's attestation that the two agents are not being layered for the same target.

## Federal and Procedural Levers

Under 29 CFR §2560.503-1(g), UHC must disclose the specific clinical rationale and the policy section invoked — a bare "duplicate therapy" reason code is non-compliant and grounds for a de novo external review demand. 29 CFR §2590.712 (NQTL parity) matters when the overlap involves a behavioral comorbidity managed by Optum Behavioral Health — UHC cannot apply a stricter concurrent-use NQTL to a biologic than it applies to comparable medical drugs. For self-funded ERISA plans, Pinto v. Aetna Life Ins. Co., 761 F.3d 1175 (10th Cir. 2014), places the experimental/medical-necessity burden on the plan; force UHC to articulate the clinical evidence that the specific drug combination is contraindicated, not merely that two immunomodulators appear on the claim file. Medicare Advantage members get a separate 42 CFR §422.566 reconsideration pathway with a 7-day standard / 72-hour expedited clock.

## Tactical Tip

Before filing, run the UHC Provider Portal eligibility check and screenshot every active and terminated authorization for both drugs. Submit a one-page "concurrent therapy reconciliation" cover sheet showing dose dates, indication-by-indication mapping, and washout. Nine out of ten duplicate-therapy denials reverse at the first-level peer-to-peer once the reviewer sees the timeline — demand the P2P within 72 hours and name the policy bulletin section in writing.